ROBIN COOK—New York Times-best selling author and master of the medical thriller—returns with another crackling tale of unchecked greed, medical malfeasance, adn starling science. PIA GRAZDANI is an exceptional yet aloof medical student working closely with Columbia University Medical Center's premier scientist on cutting-edge research that could revolutionize health care by creating replacement organs for critically ill patients. Thorough her work with the brilliant molecular geneticist Dr. Tobias Rothman, Pia knows she will be given the chance to fulfill her ambition to participate in medical discoveries that can help millions while bringing her a measure of personal peace that might once and for all push aside memories of her difficult and abusive childhood.But when tragedy strikes in the lab, Pia, with the help of infatuated classmate George Wilson, must investigate the unforeseen calamity in the hospital's supposedly secure biosafety lab. Meanwhile, two ex-Wall Street whiz kids think they have found another loadstone in the nation's multi-trillion dollar life insurance industry. They race to find ways to control actuarial data and securitize the policies of the aged and infirm to make another killing. As Pia and George dig deeper into the events at the lab one question remains unanswered: is someone attempting to manipulate private insurance information to allow investors to benefit from the deaths of others?

After a tumultuous year in which her mentor is murdered and her estranged father comes back into her life, Pia Grazdani, the embattled medical student from Death Benefit, decides to take a year off from her medical studies and escape New York City. Intrigued by the promise of the burgeoning field of medical technology and the chance to clear her head, Pia takes a job at Nano, LLC, a lavishly funded, security-conscious nanotechnology insititute in the picturesque foothills of the Rockies. Nano, LLC is ahead of the curve in the competitive world of molecular manufacturing, including the construction of microbivores, tiny nano-robots with the ability to gobble up viruses and bacteria. But the corporate campus is a place of secrets. She's warned by her boss not to investigate the other work being done at the gigantic facility, nor to ask questions about the source of the seemingly endless capital that funds the institute's research. And when Pia encounters a fellow employee on a corporate jogging path, suffering the effects of a seizure, she soon realizes she may have literally stumbled upon Nano LLC's human guinea pigs. Is the tech giant on the cusp of one of the biggest medical discoveries of the twenty-first century—a treatment option for millions—or have they already sold out to the highest bidder?